8589 Background: Indolent lymphomas are the most common non-Hodgkin’s lymphomas (NHL). The cell adhesion molecules CD44, ICAM-1 and VCAM-1 present on lymphoma cells regulate cell-matrix interactions and lymphocyte migration. Elevated serum levels of CD44, ICAM-1 and VCAM-1 have been linked to poor prognosis in high grade lymphomas but their utility in low grade lymphomas remains undefined. Methods: To determine the clinical significance of CD44, ICAM-1 and VCAM-1 levels in patients with indolent NHL, we evaluated outcomes of 100 patients with newly diagnosed indolent NHL in relation to their CD44, VCAM-1 and ICAM-1 levels at presentation. All 3 markers were measured using commercially available ELISA kits. Median values of markers obtained from preliminary data analysis (CD44: 540 ng/ml, ICAM-1: 300 ng/ml VCAM-1: 1120 ng/ml) were used as cutpoints for analysis. Kaplan-Meier curves and the log-rank test were used to compare the difference in survival between the serum marker high and low groups. Multivariate analysis was done with Cox proportional hazard models. Tests were two-sided; p-values less than 0.05 were considered statistically significant. Results: Of 93 evaluable patients followed for a median of 15.2 years, 62% relapsed and 47% died. On univariate analysis elevated CD44, ICAM-1 and VCAM-1 were significantly associated with worse overall survival (OS) and relapse free survival (RFS). The predictive value of CD44, ICAM-1 and VCAM-1 for overall survival persisted even when only stage IV patients were analyzed (p<0.05). However, none of the serum markers were independent predictors of OS or RFS in a multivariate analysis that included the Follicular Lymphoma International Prognostic Index (FLIPI) score. Conclusions: Serum levels of the cell-adhesion molecules CD44, ICAM-1, and VCAM-1 are accurate predictors of outcome in patients with indolent NHL. The prognostic value is maintained within the sub-population of Stage IV patients. Unlike the FLIPI, which is limited to initial presentation, cell adhesion molecules may hold promise as serum biomarkers of response to therapy or progression of disease. No significant financial relationships to disclose.